Trial reportClinical and experimental dermatology2022
Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis.
Trial report in Clinical and experimental dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03901144 (A Phase 2 Randomised Controlled Trial of a NOVel Moisturiser for Atopic Dermatitis), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Randomised Controlled Trial of a NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier in Adults With a Predisposition to a Skin Barrier Defect
Who cites it
20 citing papers in PubMed, 60 citations in OpenAlex.
- Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT.Health technology assessment (Winchester, England) · 2024Trial
- Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel.Dermatology and therapy · 2026Review
- Effects of a Moisturizer and Emollient on the Stratum Corneum Assessed by Confocal Raman Spectroscopy in Patients With and Without Atopic Dermatitis: An Assessor-Blinded Prospective Cohort Study.Health science reports · 2026Article
- The association between polyunsaturated fatty acids in breast milk and infant eczema and its relationship with infant gut microbiota.Asia Pacific journal of clinical nutrition · 2026Article
- Clinical Measurement of Transepidermal Water Loss.Advances in wound care · 2026Review
- Isosorbide Diesters: Mechanistic Insights and Therapeutic Applications in Skin and Neuroinflammatory Disorders.International journal of molecular sciences · 2025Review
- A Comprehensive Review on the Valorization of Bioactives from Marine Animal By-Products for Health-Promoting, Biofunctional Cosmetics.Marine drugs · 2025Review
- Flavonoids as Natural Anti-Inflammatory Agents in the Atopic Dermatitis Treatment.Pharmaceutics · 2025Review
- Effect of topical treatment with urea in ichthyosis, atopic dermatitis, psoriasis, and other skin conditions-a systematic review.Annals of medicine and surgery (2012) · 2025Article
- Skin Barrier Repair and Nursing Care in Patients with Atopic Dermatitis: A Narrative Review.International journal of general medicine · 2025Review
- Biologically Active Sheep Colostrum for Topical Treatment and Skin Care.International journal of molecular sciences · 2024Article
- Parental Attitudes and Practices regarding Atopic Dermatitis: A Cross-Sectional Study among a Thai Population.Children (Basel, Switzerland) · 2024Article
- Topical steroids or emollients: does order matter?Archives of dermatological research · 2024Review
- Skin microbiota: pathogenic roles and implications in atopic dermatitis.Frontiers in cellular and infection microbiology · 2024Review
- The Role of Moisturizer Containing Anti-inflammatory on Skin Hydration in Mild-Moderate Atopic Dermatitis Patients.Dermatology research and practice · 2024Article
- Non-invasive assessment of skin hydration and sensation with diffuse reflectance spectroscopy.Scientific reports · 2023Article
- [This is how I deal with corticosteroid-induced skin atrophy].Zeitschrift fur Rheumatologie · 2023Article
- Targeting Skin Barrier Function in Atopic Dermatitis.The journal of allergy and clinical immunology. In practice · 2023Article
- Patient-Centric Design of Topical Dermatological Medicines.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Moisturizer in Patients with Inflammatory Skin Diseases.Medicina (Kaunas, Lithuania) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundEczema (atopic dermatitis; AD) is a very common itchy skin condition affecting 1 in 5 children and up to 1 in 10 adults worldwide. The skin of eczema sufferers is prone to redness, irritation and dryness because it does not form an effective barrier, i.e. the ability of the skin to stop irritants, allergens and microorganisms getting into the body. Skin barrier dysfunction is a hallmark of AD. The regular and liberal (600 g/week for an adult) use of emollients is recommended for all patients with eczema), even between episodes of itching and redness, to soften and soothe the skin. In England alone, almost 9 million prescriptions for emollient creams were issued in 2018, at a cost of over £50 million. Despite this widespread use, relatively little is known about how commonly prescribed emollient creams affect the skin's barrier, and thus the role of moisturizers in AD development and progression remains unclear. We set out to compare three different types of emollient cream and a no-treatment control.
aimTo compare the barrier-strengthening properties of a new moisturizer containing urea and glycerol (urea-glycerol cream; UGC), with those of a glycerol-containing moisturizer (glycerol cream; GC), a simple paraffin cream (PC) with no humectant, and a no-treatment control (NTC).
methodsThis was an observer-blinded prospective Phase 2 within-subject multilateral single-centre randomized controlled trial in adults with AD (Clinical Trials #NCT03901144). The intervention involved 4 weeks of treatment, twice daily, with the three products applied to one of four areas on the forearms the (the fourth area was the untreated control, randomized allocation). Skin properties [dryness, transepidermal water loss (TEWL), hydration and natural moisturizing factor (NMF) levels] were assessed before, during and after treatment to see what happened to the skin's barrier. The primary outcome was skin sensitivity to the irritant sodium lauryl sulfate (SLS) after treatment. We performed tests on the skin before and after treatment to see what happened to the skin's barrier.
resultsIn total, 49 patients were randomized, completed treatment and included in the analysis. UGC significantly reduced the response to SLS as indicated by a reduction in TEWL compared with NTC (-9.0 g/m
conclusionThe study showed that not all emollient creams for eczema are equal. The simple paraffin-based emollient, which represents the most widely prescribed type of emollient cream in England, had no effect on the skin's barrier and reduced the skin's NMF. UGC markedly improved the skin's barrier and protected against irritation. GC performed better than PC, but not as well as UGC. UGC strengthened the skin barrier through a mechanism involving increased NMF levels in the skin, and imparted protection from SLS-induced irritation. By helping correct a major pathophysiological process, UGC has the potential to improve the long-term control of AD. The results show that different emollient creams have different effects on our skin, and only certain types have the ability to improve the skin's barrier and protect against irritants that trigger eczema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.